These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 3537210

  • 1. Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment.
    Caraceni TA, Girotti F, Giovannini P, Parati E.
    J Neural Transm Suppl; 1986; 22():189-99. PubMed ID: 3537210
    [Abstract] [Full Text] [Related]

  • 2. Three types of akinesia in the progressive course of Parkinson's disease.
    Narabayashi H.
    Adv Neurol; 1993; 60():18-24. PubMed ID: 8093577
    [No Abstract] [Full Text] [Related]

  • 3. Parkinson's disease. The L-dopa era.
    Yahr MD.
    Adv Neurol; 1993; 60():11-7. PubMed ID: 8420128
    [No Abstract] [Full Text] [Related]

  • 4. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
    Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN.
    Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257
    [Abstract] [Full Text] [Related]

  • 5. Pharmacotherapy of Parkinson's disease.
    Cohen MM, Scheife RT.
    Am J Hosp Pharm; 1977 May; 34(5):531-8. PubMed ID: 326045
    [Abstract] [Full Text] [Related]

  • 6. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P, Tremblay L, Féger J, Hirsch EC.
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [Abstract] [Full Text] [Related]

  • 7. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB, Murrin LC, Pfeiffer RF, Deupree JD.
    Clin Neuropharmacol; 1984 Mar; 7(3):247-57. PubMed ID: 6435870
    [Abstract] [Full Text] [Related]

  • 8. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ, Jenner P.
    Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
    [Abstract] [Full Text] [Related]

  • 9. Striatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson's disease.
    Chase TN, Engber TM, Mouradian MM.
    Adv Neurol; 1993 Sep; 60():181-5. PubMed ID: 8420133
    [No Abstract] [Full Text] [Related]

  • 10. [L-dopa therapy of parkinson syndrome].
    Kapfhammer HP, Kuss HJ, Rüther E.
    Nervenarzt; 1985 Feb; 56(2):57-68. PubMed ID: 3920542
    [No Abstract] [Full Text] [Related]

  • 11. The L-dopa on-off effect in Parkinson disease: treatment by transient drug withdrawal and dopamine receptor resensitization.
    Direnfeld L, Spero L, Marotta J, Seeman P.
    Ann Neurol; 1978 Dec; 4(6):573-5. PubMed ID: 742858
    [Abstract] [Full Text] [Related]

  • 12. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM, Nowak P, Kostrzewa JP, Kostrzewa RA, Brus R.
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [Abstract] [Full Text] [Related]

  • 13. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB, Bernardi G.
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [Abstract] [Full Text] [Related]

  • 14. Are "on-off" effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway?
    Carlsson A.
    J Neural Transm Suppl; 1983 Jul; 19():153-61. PubMed ID: 6321646
    [Abstract] [Full Text] [Related]

  • 15. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.
    Melamed E.
    Mt Sinai J Med; 1988 Jan; 55(1):35-42. PubMed ID: 3279303
    [No Abstract] [Full Text] [Related]

  • 16. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R.
    Neurosci Biobehav Rev; 2006 Jan; 30(1):1-23. PubMed ID: 15935475
    [Abstract] [Full Text] [Related]

  • 17. Treatment of Parkinson's disease.
    Lieberman A.
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [Abstract] [Full Text] [Related]

  • 18. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R, Lees AJ.
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [Abstract] [Full Text] [Related]

  • 19. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
    St-Hilaire M, Landry E, Lévesque D, Rouillard C.
    Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
    [Abstract] [Full Text] [Related]

  • 20. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA.
    J Neural Transm Suppl; 1995 Nov; 46():381-9. PubMed ID: 8821073
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.